DMKPQ (DMK Pharmaceuticals) Tariff Resilience Score: 0/10 (As of Jul. 01, 2026)


DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals Tariff Resilience Score?

DMK Pharmaceuticals has the Tariff Resilience Score of 0, which implies that the company might have .

DMK Pharmaceuticals has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes DMK Pharmaceuticals might have .

DMK Pharmaceuticals  (OTCPK:DMKPQ) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

DMK Pharmaceuticals Tariff Resilience Score Related Terms

DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price